Compare AbbVie Inc (ABBV) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs DigitalOcean Holdings Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while DigitalOcean Holdings Inc trades at $140.52 (market cap $14.30B). The key difference: AbbVie Inc is far larger — about 31.5× DigitalOcean Holdings Inc's market cap, and AbbVie Inc pays a 2.72% dividend while DigitalOcean Holdings Inc pays none. Which is the better fit depends on your goals.
| ABBV | DOCN | |
|---|---|---|
Market Cap | $449.91B | $14.30B |
Sector | Health | Technology |
52-Week High | $261.07 | $181.29 |
52-Week Low | $184.85 | $25.74 |
Enterprise Value | $513.38B | $14.86B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
DigitalOcean (DOCN) trades at $137.12, up 5.37% today amid strong Q2 2026 preliminary results showing accelerated growth. The stock exhibits bearish technical signals but maintains robust fundamentals with consistent earnings beats, 58.49% gross margins, and 24.97% net income margins. Recent news highlights inclusion in the Russell 1000 Index and AI-driven cloud demand, with analyst consensus bullish at a $169.91 price target.
Outlook remains positive given AI-native cloud positioning and revenue growth, though high valuation ratios (P/E 57.62) and negative shareholder equity pose risks. Upside depends on execution of growth initiatives, while competition and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
